Huttenlocher P R, Mattson R H
Neurology. 1979 Jun;29(6):763-71. doi: 10.1212/wnl.29.6.763.
An open therapeutic trial of isoprinosine was conducted in 15 patients with subacute sclerosing panencephalitis (SSPE). Long-term remissions occurred in 5 (33 percent), with documented improvement sustained for 2 or more years. Another patient was in remission 9 months after starting treatment, and three patients had transient remissions or stabilization. The disease was unaltered in five patients who had rapidly progressive SSPE when treatment started. These results compare with an average remission rate of about 5 percent in several series of untreated cases of SSPE or in cases treated with other antiviral agents. Patients in remission continued to have elevated cerebrospinal fluid (CSF) IgG and measles antibody titers, with one exception. Isoprinosine was tolerated for several years without side effects, except for mild hyperuricemia.
对15例亚急性硬化性全脑炎（SSPE）患者进行了异搏定的开放性治疗试验。5例（33%）患者实现了长期缓解，缓解状态持续记录达2年或更长时间。另1例患者在开始治疗9个月后病情缓解，还有3例患者病情短暂缓解或稳定。开始治疗时患有快速进展性SSPE的5例患者病情未改变。这些结果与几组未经治疗的SSPE病例或用其他抗病毒药物治疗的病例约5%的平均缓解率相比。除1例例外，缓解期患者的脑脊液（CSF）IgG和麻疹抗体滴度持续升高。除轻度高尿酸血症外，异搏定耐受性良好，数年内未出现副作用。
